- In 2022, Porton delivers RMB 7 billion revenue and 127% revenue growth.
- Net profit attributable to shareholders of the listed company increased 283% to RMB 2 billion.
- New POs of DP CDMO increased by 67% to RMB 119 million, and that of CGT CDMO increased by 25% to RMB 159 million
- 2023 CAPEX is expected to remain at the level of RMB 1.4-1.7 billion
Chongqing, China, 25 March 2023 – Porton Pharma Solutions Ltd. (Stock Code: 300363) has reported record revenue of RMB 7 billion, growing 127% and net profit attributable to shareholders of the listed company of RMB 2 billion, growing 283%. These robust financial results are mainly driven by strong business performance and the delivery of the material purchase orders.
In 2022, Porton continued to increase its market development and achieved continuous introduction of customers and projects. Porton has a track record of more than 2200 projects of about 800 global customers. In 2022, API CDMO, as the company’s major business segment, provided services for approximately 300 customers and delivered 449 projects, including 28 process validation projects. Two new business segments, Drug Product CDMO and Cell and Gene Therapy CDMO received new product orders with the amount of RMB 119 million and 159 million respectively.
Porton maintained investment in R&D and manufacturing capacities and capabilities. The R&D investment increased by 96.92% to RMB 520 million and our R&D team expanded to 1,330 staff. The laboratory area is expected to exceed 50,000 square meters in 2023 as our largest R&D facility in Shanghai to start operation. The API CDMO manufacturing capacity has expanded to around 2,100 cubic meters. In 2022, the Company launched the construction of the process development and production site in Slovenia, its first R&D and production facility in Europe, to further expand its globalization layout and provide global services to customers. For DP CDMO, the first phase of the manufacturing site with three production workshops for solids and two for injections was put into use in 2022. For CGT CDMO, the industrial base in Suzhou was put into use in December, after which there are over 20,000 square meters of process development and production workshops for the CGT capacity with ten production lines of GMP viral vectors, 12 production lines of GMP cell therapy and hundreds of clean workshops.
Porton has announced 2023 CAPEX guidance to remain at the level of RMB 1.4-1.7 billion to continue capability construction, including manufacturing capacities, R&D facilities and strategic new capabilities such as peptides, Oligonucleotides, ADCs and biologics.
Oliver Ju, Chairman and CEO of Porton, commented, “2022 is an important milestone during Porton’s 17 years history. Despite the challenging macro environment, Porton secured and successfully delivered its largest orders and achieved record performance in 2022. With the operational cash flows generated, Porton accelerated its capacity expansion and capability enhancement so as to realize its strategic goal to build an end-to-end global pharmaceutical service platform. ”
Moving into 2023, Porton enters a new three-year strategic cycle. By combining long-term and short-term goals, we will focus on six strategies which are “achieving breakthroughs in key business opportunities, developing new businesses, making breakthroughs in key technologies, marketing reform, digital transformation, and globalization.” By achieving breakthroughs in key markets, key customers, and key products, Porton will continue to invest and transform its core business and organizational capabilities to enhance customer value and business competitiveness, as well as to maintain its long-term competitiveness. At the same time, we will continue to focus on operational efficiency, achieve cost savings and efficiency gains through innovation and transformation.
About Porton
Founded in 2005, Porton Pharma Solutions Ltd. is a global CDMO provides one-stop services for small molecule drugs, peptides, oligonucleotides, biologics and gene & cell therapy during the entire life cycle from preclinical research to drug approval for global pharmaceutical companies, biotechs, scientific research institutes, etc. We are committed to providing customers with excellent end-to-end CDMO services, enabling good medicines to benefit the public earlier. As of the end of 2022, Porton has established business relationships with almost 800 global customers and has delivered more than 2,200 projects.
With more than 5,000 employees worldwide, we have R&D centers, manufacturing facilities and sales offices across China, the United States, Slovenia, Belgium, Switzerland and Denmark.
Find out more at https://www.portonpharma.com/index.html